Code Biotherapeutics

DNA-based Gene Therapy Vector

Undisclosed RD diabetes (1)

Code Biotherapeutics is using non-viral approaches to develop targeted delivery of genetic medicines. To rescue defects in genetic diseases DNA gene therapies can be employed, but they come with concerns and challenges. Using their proprietary, multivalent, synthetic DNA delivery platform, 3DNA®, Code Bio is overcoming the major challenges of DNA delivery such as toxicity, off-target effects and bioavailability. 3DNA® is a multivalent structure which acts as a scaffold for the attachment of nucleic acid based therapeutics and targeting molecules facilitating tissue and cell specificity. Currently, Code Bio is advancing a pipeline using their technology for diseases without a cure, such as Duchenne’s Muscular Dystrophy and Type I diabetes.